98:'s 2016 annual report, MHRP works with local programs around the world to support more than 240,000 patients on antiretroviral therapy and to make HIV testing/advising accessible to more than 1.1 million people. Using existing in-country technical expertise and administrative infrastructure, MHRP expands partnerships with local researchers, health care services and NGOs in Africa to implement PEPFAR activities. Goals include providing counseling, testing, prevention of mother to child transmission, full access to antiretroviral therapy, home-based care, and care for orphans and vulnerable children. MHRP also conducts therapeutic research, tracks the HIV epidemic in active-duty forces, assesses the risk of HIV exposure to deployed U.S. and allied forces overseas, and conducts all HIV-1 testing for the Army.
28:) was initiated by the United States Congress in 1986, in reaction to the threat of lost effectiveness of U.S./Allied troops due to HIV infection. The mission of MHRP is to develop an HIV-1 vaccine, provide prevention, care, and treatment, and conduct meaningful HIV/AIDS research for the global community through the President's Emergency Plan for AIDS Relief (PEPFAR). It is centered at the
85:
MHRP scientists are also pursuing other strategies to target multiple sub-types of HIV, including modified vaccinia virus Ankara (MVA) vaccines, which were initially developed by collaborating scientists from WRAIR, NIAID, the
National Institutes of Health, and the Laboratory of Viral Diseases (LVD).
81:
The breakthrough led to increased interest in research on RV144 and the foundation of partnerships such as the Pox-Protein Public-Private
Partnership (P5), a mosaic of public and private entities that focus on building on the success of RV144. MHRP also provides study leadership, and is working with
118:
MHRP scientists under WRAIR developed a Zika vaccine called ZIKV in only ten months, beginning clinical trial in 2016. This vaccine is not only important to maintain troop health when deploying to foreign regions where Zika is prevalent, but also for those servicemen stationed domestically because
64:
The MHRP is a $ 175 million program which receives funding for research and treatment endeavors from the
Department of Defense ($ 28 million), PEPFAR, and other organizations such as the Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases. Some of MHRP's
77:
The program's most notable contribution to HIV/AIDS medical research was the RV 144 vaccine study of over 16,000 volunteers in
Thailand. In September 2009, the MHRP and the Thai Ministry of Health conducted the first successful HIV/AIDS vaccine trial to show effective prevention in humans, with a
68:
In 2012, a MHRP scientist named Dr. Gary R. Matyas proposed a vaccine to treat heroin addiction and prevent those who received this vaccine from contracting HIV. Matyas was awarded the NIDA Avant-Garde Award for
Medications Development for this proposition, which gave him $ 1 million per year for
101:
In 2008, MHRP helped evaluate the efficacy of new Rapid
Diagnostic Tests (RDT) for HIV types 1 and 2. They were developed to be able to quickly test the blood of soldiers who transfuse blood to wounded soldiers in battle situations. This technology prevents transmission of HIV, HCV, and HBV from
114:
In 2014, MHRP's Uganda site conducted the first vaccine trial for Ebola and
Marburg virus ever done in Africa. Using combination DNA vaccines, it was shown that it is safe for people to receive both vaccines in combination. The antigens conduced by these vaccines were critical in the future
110:
Zika, Ebola, and Middle East
Respiratory Syndrome (MERS) outbreaks were responded to by MHRP, as they used their infrastructure and research experience to help develop vaccines for both local people and military personnel living in regions where those diseases were endemic.
102:
soldier to soldier and helps keep these diseases from weakening the fighting force further. Additionally, MHRP conducted the first study to characterize that current clinical testing methods can have difficulty detecting HIV viral presence in persons with acute infections.
65:
collaborative vaccine-as-treatment research is funded by
Janssen, a division of Johnson & Johnson. MHRP studies in combination approaches to HIV are made possible by a competitive grant that they competed for from a NIH-funded Martin Delaney Collaboratorive.
82:
researchers around the globe to dissect the results from the RV144 trial and to design future clinical trials to translate a scientific milestone into an eventual public health tool. RV144 remains the only instance of successful preventative HIV vaccination.
86:
MHRP has ongoing studies and clinical trials using different types of MVA vaccines in Uganda and
Thailand, with progress milestones including partial protection and viral load reduction in monkeys being infected with Simian Immunodeficiency Virus (SIV).
115:
development of stronger Ebola vaccines in Africa. In 2015, the Uganda site conducted a uniquely extensive study of Ebola survivors, finding that many were suffering from chronic malaise including hearing and vision loss up to 21 months post-infection.
837:"Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial"
119:
there are clusters of military bases in the southern United States where people are at risk for Zika. Preliminary data from a phase 1 clinical trial indicate that 92% of participants would be protected from Zika infection.
970:"Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials"
95:
53:
428:
242:
94:
In addition to vaccine research, the MHRP provides prevention, care, and treatment services to the communities where they conduct research. According to the
78:
final prevention rate of 31%. Although the efficacy is modest, this trial is significant because it proved that it is possible to develop an HIV vaccine.
1064:
435:
944:
265:"The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120"
387:
56:, most notably in the development of the RV144 HIV vaccine in Thailand. MHRP is the largest research program supported by the HJF.
411:
52:). MHRP also partners with the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Thailand. MHRP works closely with
1059:
681:"Evaluation of Performance of Two Rapid Tests for Detection of HIV-1 and -2 in High- and Low-Prevalence Populations in Nigeria"
188:
29:
611:"U.S. Military HIV Research Program: successfully integrating HIV vaccine research with prevention, care, and treatment"
509:"The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model"
429:"Sanofi Pasteur Commends Results of First HIV Vaccine Study to Show Some Effectiveness in Preventing HIV"
926:
806:
777:
650:
556:
213:
135:
835:
Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, et al. (April 2015).
507:
Hontelez JA, Nagelkerke N, Bärnighausen T, Bakker R, Tanser F, Newell ML, et al. (August 2011).
263:
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, et al. (November 2012).
1024:
164:
886:"Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study"
333:
679:
Manak MM, Njoku OS, Shutt A, Malia J, Jagodzinski LL, Milazzo M, et al. (November 2015).
459:
404:
391:
884:
Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, et al. (August 2015).
408:
8:
483:
728:
Robb ML, Eller LA, Kibuuka H, Rono K, Maganga L, Nitayaphan S, et al. (June 2016).
994:
969:
866:
754:
729:
705:
680:
533:
508:
359:"In Thailand Clinical Study, HIV Vaccine Regimen Demonstrates Modest Preventive Effect"
312:
289:
264:
985:
902:
853:
836:
358:
999:
907:
870:
858:
759:
710:
632:
538:
294:
989:
981:
897:
848:
749:
741:
700:
692:
622:
528:
520:
373:
284:
276:
32:(WRAIR), and has established five international research sites in Africa and Asia (
730:"Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand"
524:
415:
1045:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
627:
610:
54:
The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF)
1053:
1003:
911:
862:
763:
714:
636:
542:
298:
745:
585:
405:
Frequently asked questions regarding the RV144 Phase III HIV Vaccine Trial
280:
696:
388:"HIV Vaccine Study First to Show Some Effectiveness in Preventing HIV"
885:
506:
96:
Henry M. Jackson Foundation for the Advancement of Military Medicine
243:"NIDA supports development of combined anti-heroin and HIV vaccine"
49:
33:
460:"Prime-Boost Vaccine Study Shows Modest Effect in Preventing HIV"
69:
five years to continue his research at MHRP on the dual vaccine.
41:
1029:
45:
1019:
262:
37:
834:
169:
NIH: National Institute of Allergy and Infectious Diseases
883:
1039:
1034:
945:"Human Trials Begin for Army-Developed Zika Vaccine"
727:
678:
189:"Budget cuts threaten Military HIV Research Program"
1044:
390:. US Military HIV Research Program. Archived from
356:
89:
334:"For First Time, AIDS Vaccine Shows Some Success"
72:
1051:
380:
165:"U.S. Military HIV Research Program (MHRP)"
18:United States Military HIV Research Program
465:. Global Solutions for Infectious Diseases
993:
967:
901:
852:
753:
704:
626:
532:
371:
288:
1040:Global Solutions for Infectious Diseases
927:"Human trials of Zika vaccine underway"
1065:Military research of the United States
1052:
608:
331:
105:
30:Walter Reed Army Institute of Research
924:
374:"HIV vax testers react to Thai trial"
590:MHRP | Military HIV Research Program
269:AIDS Research and Human Retroviruses
799:
770:
734:The New England Journal of Medicine
643:
549:
313:"Efficacy trials - The RV144 trial"
13:
206:
14:
1076:
1013:
357:Medical News Today (2009-09-25).
128:
1020:US Military HIV Research Program
685:Journal of Clinical Microbiology
434:. Sanofi Pasteur. Archived from
961:
937:
918:
890:The Lancet. Infectious Diseases
877:
828:
721:
672:
602:
578:
500:
476:
452:
421:
365:
90:Prevention, care, and treatment
1025:Thai Ministry of Public Health
409:Thailand MHRP site information
350:
325:
305:
256:
235:
193:Science Speaks: Global ID News
181:
157:
73:International vaccine research
1:
1060:HIV/AIDS in the United States
986:10.1016/S0140-6736(17)33106-9
925:Blank C (November 30, 2016).
903:10.1016/S1473-3099(15)70152-0
854:10.1016/S0140-6736(14)62385-0
525:10.1016/j.vaccine.2011.06.059
488:Global HIV Vaccine Enterprise
122:
7:
10:
1081:
949:U.S. Department of Defense
59:
628:10.7205/MILMED-D-10-00168
807:"HJF Annual Report 2016"
778:"HJF Annual Report 2016"
651:"HJF Annual Report 2016"
557:"HJF Annual Report 2016"
372:Bob Grant (2009-09-24).
332:McNeil DG (2009-09-25).
214:"HJF Annual Report 2016"
136:"HJF Annual Report 2016"
609:Reilly L (July 2010).
746:10.1056/nejmoa1508952
394:on September 27, 2009
281:10.1089/aid.2012.0103
697:10.1128/JCM.01432-15
106:Work Outside of HIV
980:(10120): 563–571.
968:Modjarrad (2018).
414:2008-09-07 at the
847:(9977): 1545–54.
621:(7 Suppl): 42–4.
615:Military Medicine
1072:
1008:
1007:
997:
965:
959:
958:
956:
955:
941:
935:
934:
922:
916:
915:
905:
881:
875:
874:
856:
832:
826:
825:
823:
821:
811:
803:
797:
796:
794:
792:
782:
774:
768:
767:
757:
725:
719:
718:
708:
676:
670:
669:
667:
665:
655:
647:
641:
640:
630:
606:
600:
599:
597:
596:
582:
576:
575:
573:
571:
561:
553:
547:
546:
536:
504:
498:
497:
495:
494:
484:"P5 Partnership"
480:
474:
473:
471:
470:
464:
456:
450:
449:
447:
446:
440:
433:
425:
419:
402:
400:
399:
384:
378:
377:
369:
363:
362:
354:
348:
347:
345:
344:
329:
323:
322:
320:
319:
309:
303:
302:
292:
260:
254:
253:
251:
250:
239:
233:
232:
230:
228:
218:
210:
204:
203:
201:
200:
185:
179:
178:
176:
175:
161:
155:
154:
152:
150:
140:
132:
1080:
1079:
1075:
1074:
1073:
1071:
1070:
1069:
1050:
1049:
1016:
1011:
966:
962:
953:
951:
943:
942:
938:
923:
919:
882:
878:
833:
829:
819:
817:
809:
805:
804:
800:
790:
788:
780:
776:
775:
771:
740:(22): 2120–30.
726:
722:
677:
673:
663:
661:
653:
649:
648:
644:
607:
603:
594:
592:
584:
583:
579:
569:
567:
559:
555:
554:
550:
505:
501:
492:
490:
482:
481:
477:
468:
466:
462:
458:
457:
453:
444:
442:
438:
431:
427:
426:
422:
416:Wayback Machine
397:
395:
386:
385:
381:
370:
366:
355:
351:
342:
340:
330:
326:
317:
315:
311:
310:
306:
275:(11): 1444–57.
261:
257:
248:
246:
241:
240:
236:
226:
224:
216:
212:
211:
207:
198:
196:
187:
186:
182:
173:
171:
163:
162:
158:
148:
146:
138:
134:
133:
129:
125:
108:
92:
75:
62:
12:
11:
5:
1078:
1068:
1067:
1062:
1048:
1047:
1042:
1037:
1032:
1030:Sanofi Pasteur
1027:
1022:
1015:
1014:External links
1012:
1010:
1009:
960:
936:
917:
876:
827:
798:
769:
720:
691:(11): 3501–6.
671:
642:
601:
577:
548:
519:(36): 6100–6.
499:
475:
451:
420:
379:
364:
349:
338:New York Times
324:
304:
255:
234:
205:
180:
156:
126:
124:
121:
107:
104:
91:
88:
74:
71:
61:
58:
9:
6:
4:
3:
2:
1077:
1066:
1063:
1061:
1058:
1057:
1055:
1046:
1043:
1041:
1038:
1036:
1033:
1031:
1028:
1026:
1023:
1021:
1018:
1017:
1005:
1001:
996:
991:
987:
983:
979:
975:
971:
964:
950:
946:
940:
932:
928:
921:
913:
909:
904:
899:
896:(8): 905–12.
895:
891:
887:
880:
872:
868:
864:
860:
855:
850:
846:
842:
838:
831:
815:
808:
802:
786:
779:
773:
765:
761:
756:
751:
747:
743:
739:
735:
731:
724:
716:
712:
707:
702:
698:
694:
690:
686:
682:
675:
659:
652:
646:
638:
634:
629:
624:
620:
616:
612:
605:
591:
587:
586:"MVA Vaccine"
581:
565:
558:
552:
544:
540:
535:
530:
526:
522:
518:
514:
510:
503:
489:
485:
479:
461:
455:
441:on 2011-07-16
437:
430:
424:
417:
413:
410:
406:
393:
389:
383:
375:
368:
360:
353:
339:
335:
328:
314:
308:
300:
296:
291:
286:
282:
278:
274:
270:
266:
259:
244:
238:
222:
215:
209:
194:
190:
184:
170:
166:
160:
144:
137:
131:
127:
120:
116:
112:
103:
99:
97:
87:
83:
79:
70:
66:
57:
55:
51:
47:
43:
39:
35:
31:
27:
23:
19:
977:
973:
963:
952:. Retrieved
948:
939:
930:
920:
893:
889:
879:
844:
840:
830:
818:. Retrieved
813:
801:
789:. Retrieved
784:
772:
737:
733:
723:
688:
684:
674:
662:. Retrieved
657:
645:
618:
614:
604:
593:. Retrieved
589:
580:
568:. Retrieved
563:
551:
516:
512:
502:
491:. Retrieved
487:
478:
467:. Retrieved
454:
443:. Retrieved
436:the original
423:
396:. Retrieved
392:the original
382:
367:
352:
341:. Retrieved
337:
327:
316:. Retrieved
307:
272:
268:
258:
247:. Retrieved
245:. 2012-07-25
237:
225:. Retrieved
220:
208:
197:. Retrieved
195:. 2011-12-13
192:
183:
172:. Retrieved
168:
159:
147:. Retrieved
142:
130:
117:
113:
109:
100:
93:
84:
80:
76:
67:
63:
25:
21:
17:
15:
931:Drug Topics
1054:Categories
974:The Lancet
954:2018-11-07
820:26 October
791:26 October
664:26 October
595:2018-10-26
570:26 October
493:2018-10-26
469:2009-09-24
445:2009-09-24
398:2009-09-24
343:2009-09-24
318:2018-10-26
249:2018-11-07
227:26 October
199:2018-10-26
174:2018-10-26
149:26 October
123:References
1035:Genentech
871:205975536
403:Also see
1004:29217375
912:25910637
863:25540891
764:27192360
715:26311857
637:23634478
543:21703321
412:Archived
299:23035746
50:Thailand
34:Tanzania
995:5884730
755:5111628
706:4609716
534:3157643
513:Vaccine
290:3484815
60:Funding
42:Nigeria
1002:
992:
910:
869:
861:
841:Lancet
816:. 2016
787:. 2016
762:
752:
713:
703:
660:. 2016
635:
566:. 2016
541:
531:
297:
287:
223:. 2016
145:. 2016
48:, and
46:Uganda
22:USMHRP
867:S2CID
810:(PDF)
781:(PDF)
654:(PDF)
560:(PDF)
463:(PDF)
439:(PDF)
432:(PDF)
217:(PDF)
139:(PDF)
38:Kenya
1000:PMID
908:PMID
859:PMID
822:2018
793:2018
760:PMID
711:PMID
666:2018
633:PMID
572:2018
539:PMID
407:and
295:PMID
229:2018
151:2018
26:MHRP
16:The
990:PMC
982:doi
978:391
898:doi
849:doi
845:385
814:HJF
785:HJF
750:PMC
742:doi
738:374
701:PMC
693:doi
658:HJF
623:doi
619:175
564:HJF
529:PMC
521:doi
285:PMC
277:doi
221:HJF
143:HJF
24:or
1056::
998:.
988:.
976:.
972:.
947:.
929:.
906:.
894:15
892:.
888:.
865:.
857:.
843:.
839:.
812:.
783:.
758:.
748:.
736:.
732:.
709:.
699:.
689:53
687:.
683:.
656:.
631:.
617:.
613:.
588:.
562:.
537:.
527:.
517:29
515:.
511:.
486:.
336:.
293:.
283:.
273:28
271:.
267:.
219:.
191:.
167:.
141:.
44:,
40:,
36:,
1006:.
984::
957:.
933:.
914:.
900::
873:.
851::
824:.
795:.
766:.
744::
717:.
695::
668:.
639:.
625::
598:.
574:.
545:.
523::
496:.
472:.
448:.
418:.
401:.
376:.
361:.
346:.
321:.
301:.
279::
252:.
231:.
202:.
177:.
153:.
20:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.